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Abstract
Background: Hirschsprung Disease (HSCR) is a congenital defect of the intestinal innervations characterized by
complex inheritance. Many susceptibility genes including RET, the major HSCR gene, and several linked regions and
associated loci have been shown to contribute to disease pathogenesis. Nonetheless, a proportion of patients still
remains unexplained. Copy Number Variations (CNVs) have already been involved in HSCR, and for this reason we
performed Comparative Genomic Hybridization (CGH), using a custom array with high density probes.
Results: A total of 20 HSCR candidate regions/genes was tested in 55 sporadic patients and four patients with
already known chromosomal aberrations. Among 83 calls, 12 variants were experimentally validated, three of which
involving the HSCR crucial genes SEMA3A/3D, NRG1, and PHOX2B. Conversely RET involvement in HSCR does not
seem to rely on the presence of CNVs while, interestingly, several gains and losses did co-occur with another RET
defect, thus confirming that more than one predisposing event is necessary for HSCR to develop. New loci were
also shown to be involved, such as ALDH1A2, already found to play a major role in the enteric nervous system.
Finally, all the inherited CNVs were of maternal origin.
Conclusions: Our results confirm a wide genetic heterogeneity in HSCR occurrence and support a role of
candidate genes in expression regulation and cell signaling, thus contributing to depict further the molecular
complexity of the genomic regions involved in the Enteric Nervous System development. The observed maternal
transmission bias for HSCR associated CNVs supports the hypothesis that in females these variants might be more
tolerated, requiring additional alterations to develop HSCR disease.
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Background
Hirschsprung Disease (HSCR) (OMIM# 142623) is a con-
genital intestinal aganglionosis caused by a premature ar-
rest of the cranio-caudal migration of neural crest cells
during embryogenesis, showing an incidence of around 1/
5000 live births [1]. The phenotype is highly variable, with
severity classified according to the length of the affected
gastrointestinal tract as short-segment HSCR (agangliono-
sis does not extend beyond the upper sigmoid, S-HSCR:
80% of cases) and long-segment HSCR (L-HSCR: 20% of
cases). About 70% of cases presents as isolated, while 30%
shows additional anomalies, including chromosomal aber-
rations [1]. HSCR is characterized by increased sibling re-
currence risk varying by gender, length of aganglionosis
and familial occurrence (up to 80% of cases are sporadic).
These observations, together with a distorted sex ratio (M:
F = 4:1), make HSCR a model for complex genetic disease.
Genetic heterogeneity in HSCR is demonstrated by in-
volvement of several genes and loci [2–4]. The major gene
involved in isolated HSCR is the RET proto-oncogene [1],
located on 10q11.2 and linked to HSCR in 90% of the fa-
milial forms [3]. In addition, HSCR has been associated
with several RET polymorphisms, most of which part of a
common risk haplotype encompassing the RET gene
from the promoter to exon 2 [5–8]. An association
with NRG1 (OMIM# 142445) and SEMA3A (OMIM#
603961) / SEMA3D (OMIM# 609907) has also been de-
scribed [9–11]. However, a proportion of HSCR patients
still remains unexplained as only 50% of familial and 7–
35% of sporadic HSCR cases can be explained by RET
coding variants [1]. Deletions in genes already known to
be involved in HSCR might account for these latter cases.
Indeed, the RET gene was discovered following observa-
tion of de novo interstitial deletions of 10q11.2 [12, 13]
and about 12% of HSCR patients have structural abnor-
malities [1].
Copy number variations (CNVs), already proven to be
genetic risk factors in disease pathogenesis [14, 15], might
thus account for part of the missing heritability in HSCR.
Jiang et al. (2011) performed a custom-designed array
CGH to examine 67 candidate HSCR genes in 18 HSCR
patients, identifying seven CNVs at three loci, all likely
hosting regulatory genes in syndromic HSCR patients
[16]. On the other hand, Tang et al. (2012) assessed the
CNV contribution to HSCR from genome-wide SNP data
finding a greater burden for rare CNVs in HSCR cases
over controls and larger CNVs in syndromic HSCR than
in isolated cases. Only six CNVs overlapped with known
HSCR loci, none involving the RET gene [17]. Another
study investigated 123 HSCR patients and 432 unaffected
subjects, with Illumina’s HumanOmni1-Quad BeadChip,
finding 16 CNV regions associated with HSCR [18]. Fi-
nally, very recently, Tilghman et al. (2019) have dissected,
through both karyotyping and exome sequencing, the
differential contribution to HSCR development of three
different molecular classes of risk alleles, namely rare cod-
ing variants, common non coding variants and large
CNVs and chromosomal anomalies. In this latter class, at
least 9 loci have been reported, whose aberrations showed
a very high odd ratio (63.07) and are involved in 11.4% of
the patients [19].
To further explore genetic heterogeneity in HSCR, we
have performed CGH, using a custom array with high
density probes and focusing on a total of 20 candidate
regions/genes already known to be involved in HSCR,
on a selected panel of 55 sporadic HSCR previously ge-
notyped at the RET locus [6] and four HSCR patients
with already known chromosomal aberrations.
Results
HSCR patients and regions analyzed
A total of 55 Italian sporadic HSCR patients fully geno-
typed at the RET locus [6] were retrospectively included
in the study. To investigate the possible presence of
interstitial deletions of the RET region, we selected 52
cases homozygous for the risk haplotype [5–8] as well as
3 patients carrying very uncommon haplotypes, consist-
ent with possible hemizygosity of the same region. Four
additional HSCR patients were included as positive con-
trols: two with a de novo deletion at the centromeric re-
gion of chromosome 10 [12, 13], one with an inverted
duplication at chromosome 22, and another one with a
trisomy 21 (in addition to two HSCR patients already in-
cluded in the sample set and presenting with Down syn-
drome, OMIM# 190685). The whole sample analyzed is
thus constituted by 59 HSCR patients.
Besides the major RET gene, other candidate genes
and loci were selected for the analysis based on i) linkage
with HSCR, ii) association with the disease, iii) mutation
in syndromic and isolated HSCR patients, iv) involve-
ment in the transcriptional regulation of RET, and v)
preliminary evidence, not confirmed later. Finally, other
loci were included because altered in disorders present-
ing HSCR with a higher prevalence than the general
population (Table 1).
Aberrations detected
The selected HSCR patients and positive controls under-
went custom aCGH. As reported in Additional file 1, a
total of 75 calls were estimated from the raw data using
the Agilent Aberration Detection method as described
under Methods. Two of these calls corresponded to
already known trisomies of chromosome 21, and four
calls identified the alterations included as controls.
In addition, we evaluated the profiles of all the samples
by visual inspection. This allowed us to add 6 calls to
the list of aberrations, undetected by the software. Fi-
nally, although we did not expect any new variant in
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replicates, in a triplicate sample we found two aberra-
tions that had not been detected in the array firstly
investigated, but were present in both the two replicates
and thus assumed as reliable, for a total of 83 aberra-
tions detected in 64 different chromosomal locations in
44 samples (Additional file 1, Figure S1). Twenty-six of
these aberrations had previously been reported on DGV;
all of them were common CNVs (frequency > 5%), with
the exception of the deletion at SEMA3A/3D, that is
compatible with two CNVs detected by sequencing [26,
27] with an overall frequency of less than 1% (Table 2,
Additional file 1: Figure S1). Four of the CNVs common
in DGV were recurrent in the samples. The variants at
15q11 and 5q13, and the gain at 9p11, common on
DGV, showed frequencies roughly similar to those re-
ported for controls in the high resolution gnomAD
(https://gnomad.broadinstitute.org/) and deciphering
developmental disorders (DDD) (https://decipher.sanger.
ac.uk/) databases [28, 29]. Losses at 9p11 and 9q31 had
frequencies in between gnomAD and DDD. Interest-
ingly, variants on 22q11.2 were all but one more fre-
quent in our sample (Additional file 2). Moreover, three
regions, found to carry anomalies in 5 samples, are com-
patible with CNVs reported on the Decipher database.
The region 22:25672585–25,892,401 was found dupli-
cated in two patients and deleted in a third patient, with
anomalies also reported on DGV, with frequencies simi-
lar to controls in gnomAD and DDD and regarded as
likely benign common CNVs. Also the deletion at 9:
113025039–113,029,430 is common on DGV and likely
benign, but interestingly it is reported in a patients af-
fected by aganglionic megacolon, intellectual disability
and short stature. Finally, the deletion at 1:146638075–
149,224,043 is compatible with several deletions reported











reason for selectinga references
selected RET 10q11.2 300 nt 100 kb 813 linkage, mutation, association [1]
9q31 9q31 2.5 kb 0 kb 1824 linkage [3]
9p24.1 9p24.1 3.5 kb 0 kb 142 preliminary data unpublished
PHOX2B 4p13 500 nt 10 kb 49 association, transcriptional, HSCR
increased prevalence
[1, 20, 21]
NRG1 8p12 500 nt 10 kb 473 association [9, 22]
SEMA3A/3D 7q21.11 2.5 kb 10 kb 508 association [10, 11, 22]
6q25.1 6q25.1 3.5 kb 0 kb 714 preliminary data unpublished
21q22 21q22 50 kb 0 kb 202 HSCR increased prevalence [1]
3p21 3p21 3.5 kb 0 kb 1141 linkage [4]
19q12 19q12 3.5 kb 0 kb 1085 linkage [4]
NRTN 19p13.3 800 nt 5 kb 18 mutation [1]
16q23.3 16q23.3 3.5 kb 0 kb 714 linkage [23]
NKX2–1 14q13 800 nt 5 kb 17 transcriptional, mutation [24]
SOX10 22q13 800 nt 5 kb 27 transcriptional [1]
22q11.2 22q11.2 50 kb 0 kb 162 HSCR increased prevalence [25]
ECE1 1p36.1 800 nt 5 kb 103 mutation [1]
ZEB2 2q22.3 800 nt 0 kb 165 mutation [1]
EDNRB 13q22 800 nt 5 kb 112 linkage, mutation [1]
GDNF 5p13.1-
p12
800 nt 5 kb 42 mutation [1]
EDN3 20q13.2-
q13.3







a linkage = reported in linkage with HSCR; mutation = reported as mutated in isolated HSCR; association = found associated with HSCR; transcriptional = suggested
as involved in HSCR due to transcriptional evidences; preliminary data = suggested as deleted or amplified by preliminary results, later not confirmed; HSCR
increased prevalence = increased prevalence of HSCR among patients with disorders caused by these genes/loci
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on decipher including the 1q21.1 recurrent microdeletion
(OMIM# 612474).
In conclusion, excluding the control regions and
chromosome 21 for the two Down syndrome HSCR pa-
tients, we have detected 51 novel aberrations, plus the
one reported on DGV with very low frequency (Add-
itional file 1, Figure S1). As two of these variants were
recurrent in three patients each, we had a total of 48 dis-
tinct variants detected in 25 patients. Several of them
looked unlikely at the visual inspection and, as a matter
of fact, mainly not confirmed on the replicate, when
available. Conversely, most of the variants classified as
likely or possible at the visual inspection were also repli-
cated [30] (Additional file 1).
CNVs already reported in HSCR
Despite 41 aberrations were called at the RET locus in
40 samples, they were barely overlapping and rarely lo-
cated on the risk haplotype. Only two of them were con-
sidered after applying the MALR> 0.30 criteria (see
Methods), but no one looked as likely at visual inspec-
tion and could be confirmed at validation, proving that
those CNVs were false positive. Therefore, neither dele-
tions hypothesized based on homozigosity nor very rare
haplotypes compatible with hemizygous conditions were
sustained by the present data.
Most of the regions reported as duplicated or deleted
in other studies [16, 17] were not included in our se-
lected regions, neither we could detect any aberration
comparable with those already reported when covered
by probes in our design.
Variant validation and parental origin
We elected to focus on gains/losses that seemed more
promising at the visual inspection (classified as likely)
and not reported on DGV, in addition to one deletion of
the SEMA3A/SEMA3D region, compatible with a CNV
reported on DGV but with a low frequency. We in-
cluded also three aberrations unlikely at the visual in-
spection but particularly interesting as located in the
SEMA3A/SEMA3D region and the RET locus, two mas-
ter loci in HSCR development [1, 10, 11]. We have thus
selected for validation 18 aberrations found in 14 pa-
tients (Table 3, Fig. 1, Fig. 2, Additional file 1).
Eleven of these 18 aberrations were confirmed in 11
patients (Table 3), including one variant that gave no
conclusive results by validation with a different method
but was confirmed on a replicate. Seven were instead
not confirmed, mostly of which on RET and/or already
considered as unlikely after visual inspection. In
addition, one variant initially not selected for validation,
because considered unlikely at the visual inspection, was
confirmed on a replicate and resulted recurrent in two
other samples that have not been further analyzed.
Interestingly, some of these 12 true novel aberrations in-
volved the NRG1, SEMA3A/SEMA3D and PHOX2B
loci, three of the strongest candidates among our target
regions. In particular, the short deletion detected be-
tween exon 6 and 7 of NRG1 affected a male isolated pa-
tient with L-form HSCR, the ~ 9 kb deletion in
SEMA3A/3D was intergenic (between SEMA3A and
SEMA3D), and was inherited from the mother by a male
S-form HSCR isolated patient. We could also detect a
deletion that involved almost the entire PHOX2B gene
in a female isolated S-form HSCR patient, shown to be
inherited by the mother. Other CNVs were found at
known HSCR candidate loci 9q31 [3] (in four patients,
although not overlapping between each other and cover-
ing a gene in only one patient), 16q23.3 (a short inter-
exonic gain) [23], and 19q12 (not involving any known
gene) [4]. In addition, a CNV recurrent in three samples
has been detected at 22q11.2, a locus affected in
DiGeorge and VeloCardioFacial syndromes, and in der
(22) and Cat-Eye syndrome, disorders presenting HSCR
with a higher prevalence than the general population
[31]. Finally two CNVs, at 1q21 and 15q21, were found
outside any of the HSCR candidate loci represented at
high-density probes in the array (Table 3). Among these
12 losses and gains found in 11 patients, the M/F rate
was 7/4, with an enrichment in females with respect to
the whole sample analyzed (from 28.8 to 36.4%), seven
patients had an S-form (70.0% with respect to 58.8% for
the whole sample analyzed), while three were L and one
unknown (Table 4). Nine were isolated cases, while one
patient had Down syndrome and another one presented
with cardiac and facial malformations. Finally, 5 patients
carried either RET variants or RET locus deletions, with
increased frequency of RET anomalies with respect to
the original sample (45.5% vs 23.7%). Interestingly, the
four patients with aberrations at 9q31 were all defective
for RET.
No difference in the distribution of patients’ charac-
teristics was detected compared to the whole sample
analyzed, when considering both the newly detected
77 aberrations and the “true” 37 CNVs detected. In-
deed, in both cases the median size of CNVs was lar-
ger among syndromic patients than among isolated
cases: 1,5 Mb vs 16.5 Kb in 9 and 68 newly detected
CNVs in syndromic and isolated patients respectively,
and 2.8 Mb vs 514 Kb in 5 and 32 “true” CNVs, with
a borderline p-value (p = 0,0866), as already reported
by others [17]. No difference was detected instead
with regards to patients gender, while RET negative
patients carried CNVs larger on average than RET
mutated patients.
While parents were not available for three patients,
and only one gain showed to be de novo, all the other
seven validated CNVs resulted inherited by unaffected
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Fig. 1 (See legend on next page.)
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mothers and none by fathers (100%, exact confidence
interval from 59 to 100%, p = 0.0078).
Discussion
We have performed a high density custom array-CGH
to search for DNA copy imbalances at selected candidate
genes and loci in a total of 59 HSCR patients. Despite
our interest on the RET gene, we could not detect any
novel variant at this locus, in line with what reported by
others [16–18, 25, 32]. Moreover, the RET locus pre-
sented with false positive calls, confirming the difficulties
raised by this subcentromeric region. Also other genes,
previously investigated for deletions and amplifications
(ZEB2, EDN3 and GDNF), did not show any alteration
[16, 32]. At opposite, we could detect CNVs at two loci,
1q21 and 15q21 (Fig. 2), never implicated in HSCR be-
fore, by probes randomly selected to cover the whole
genome at low density.
Unfortunately, given the uneven probes distribution of
the present design, we could not assess the possible
CNVs enrichment in HSCR candidate genes with respect
to the other chromosomal regions. Nonetheless, data
from controls were looked up in the high resolution da-
tabases gnomAD and DDD [28, 29] and analyzed to in-
vestigate the CNVs detected in our panel of HSCR cases.
As shown in the Additional file 2, we were able to dem-
onstrate the presence of several novel deletions/duplica-
tions in candidate genes and loci and to suggest an
enrichment of common CNVs in 22q11.2 over controls.
9q31 and 9p11 losses have resulted with a frequency sig-
nificantly different compared to both the control data-
bases. However, as these latter control frequencies are
very different from each other, a degree of discordance
can be hypothesized between the control sets of these
two databases.
Linkage of HSCR to 9q31 was shown in families with
no or hypomorphic RET gene mutations, suggesting that
these latters would require the action of other defects
[3]. Novel chromosomal variants at locus 9q31 were
confirmed in our dataset in 4 out of 59 patients, who
also carried either heterozygous missense variants of the
RET gene or large deletions at the RET locus, associa-
tions consistent with the digenic inheritance of HSCR
already suggested [3, 19]. Other studies have pointed to
9q31 as a region involved in HSCR, but only a few
suggestive causative genes have been identified so far.
Among these, IKBKAP (OMIM# 603722) was found asso-
ciated with HSCR in Chinese samples, especially in pa-
tients carrying RET coding variants [33], suggesting
population specificity and implying that, in agreement
with our observations, RET variants are found to co-occur
with additional chromosomal anomalies. Interestingly,
despite lack of concordance about HSCR gene(s) on 9q31,
a quantitative linkage analysis carried out on genes likely
involved in the enteric nervous system development iden-
tified a “master regulator” locus in 9q31 [34].
We also detected novel CNVs in SEMA3A/3D, NRG1
and PHOX2B (Fig. 2). Class 3 Semaphorins, known to be
involved in neuronal migration, proliferation, survival,
and axonal guidance [35], have been demonstrated to be
HSCR susceptibility factors [10, 11]. The importance of
SEMA3D signaling in the ENS is further supported by
gene expression comparison between wild-type and Ret
k−/k- mouse gastrointestinal tracts [36]. Neuregulin 1
(NRG1) is essential for the development of the nervous
system and the heart and its deregulation has been
linked to cancer, schizophrenia and bipolar disorder
(BPD) (OMIM# 181500) [37]. NRG1 has also been iden-
tified as an additional HSCR susceptibility locus in Asian
populations [9, 38]. Such an association, found initially
to be below genome-wide significance in Caucasians [22,
39], has been demonstrated also in an European popula-
tion [40]. Moreover, NRG1 expression has been found to
be significantly higher in HSCR than in controls tissues
[41]. An interplay between RET and NRG1 has been sug-
gested [2]. We could also detect a deletion of the
PHOX2B gene, a gene that codes for a homeodomain
transcription factor involved in the development of sev-
eral noradrenergic neuronal populations in the autono-
mous nervous system [1]. Different heterozygous
mutations of PHOX2B are known to cause Congenital
Central Hypoventilation Syndrome (CCHS) (OMIM#
209880), a rare disease characterized by impaired venti-
lator response to hypercapnia and hypoxia, often associ-
ated with HSCR and neuroblastomas [1]. A PHOX2B
interstitial deletion, as well as PHOX2B mutations, have
been reported in HSCR patients [20, 21]. Moreover, in-
frame deleted and common polyA contracted alleles of
the PHOX2B gene have shown to either abolish or re-
duce the transactivation activity of the mutant proteins,
(See figure on previous page.)
Fig. 1 Diagram of the study design. Flowchart of the analysis performed on the complete panel of 59 patients, including the Agilent informatic
method (on the left) and the visual inspection (on the right), that have led to the detection of 83 CNVs, together with the tables and files
generated at each step. In particular, excluding the six already known control CNVs, the remaining 77 are further distinguished based on the DGV
database (25 CNVs with a frequency higher than 5%, and thus considered true, and 52 CNVs novel or very rare on DGV) and on a visual
classification. Fifteen likely true CNVs and three CNVs located on known HSCR genes have been validated by a different approach, confirming a
total of 12 novel “true” CNVs in addition to the 25 already described on DGV. Numbers shown on the top of the diagram (above the red line)
refer to samples, while those shown below the red line refer to CNVs (not coincident with the number of samples carrying the CNVs)
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respectively [21, 42]. Therefore our results support
PHOX2B loss-of-function as a rare cause of the HSCR
phenotype.
We also confirmed one aberration affecting 19q12, a
locus found to be in linkage with HSCR [4], and de-
tected a de novo gain at locus 16q23.3 (Fig. 2), previ-
ously identified by a genome-wide association study in
43 Mennonite family trios [23]. The only known gene in
this region is MPHOSPH6 (M-phase PHOSPHoprotein6)
(OMIM# 605500), an exosome-associated protein that is
phosphorylated during mitosis [43].
In addition, we found quite large aberrations in two
regions not included among the selected candidate loci.
The 15q21.3 locus contains several genes, among which
Fig. 2 Profiles for some validated CNVs. Copy Number Variation (CNVs) detected at 9q31 (a), 15q21 (b), 16q23 (c) and PHOX2B (d) are shown. On
the left of each panel there is the chromosomal view, on the middle the detailed region view with genes reported, and on the right the possible
presence of CNVs
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ALDH1A2 (Aldehyde Dehydrogenase 1 Family, Member
A2) (OMIM# 603687) is particularly interesting, coding
for an enzyme that catalyzes the synthesis of retinoic
acid (RA) from retinaldehyde. RA is a hormonal sig-
naling molecule critical during embryonic develop-
ment, that has already been documented as a
regulator of RET expression in cardiac and renal de-
velopment, to delay the colonization of the hindgut
by RET-positive enteric neuroblasts, and to result in
ectopic RET expression during embryogenesis. RA has
also been proposed to maintain migratory signals and
deficiency of its precursor, Vitamin A, and could
therefore increase HSCR penetrance and expressivity
[44]. Finally, targeted inactivation of the mouse
aldh1a2 has been shown to lead to agenesis of the
enteric ganglia, a condition reminiscent of human
Hirschprung’s disease [44]. Another interesting gene
in the same region is ADAM10 (OMIM# 602192), a
member of the ADAM family, cell surface proteins
with both adhesion and protease domains, which
cleaves TNF-alpha, E-cadherin, L1cam and other
proteins, besides regulating Notch signaling, a process
required for progenitor cell lineage specification and
maintenance [45].
The deletion in 1q21.1-q21.2 spans the 1q microdele-
tion syndrome region, increasing the risk of delayed de-
velopment, intellectual disability, physical abnormalities,
and neurological and psychiatric problems. Recently, a
deletion and two duplications at locus 1q21.1 have been
detected in HSCR patients and reported as significantly
overrepresented compared to controls, thus confirming
the consistency of our result [19]. The patient carrying
this maternally inherited deletion is a female with S-
form HSCR without any RET coding variant, reported to
present ventricular septal defect (VSD), mandibular hy-
poplasia, and low-set ears. As far as we know, this is the
first case reported of 1q21 microdeletion syndrome asso-
ciated with HSCR.
In our study, we have elected to focus on CNVs never
reported on DGV database. Surprisingly, seven out of 8
of such novel and confirmed CNVs were inherited by
the unaffected mothers, while the eighth one had a de













L/TCA 21 16 12 9 3
S/ultraS 30 21 15b 9 7
unknown 8 5 4 3 1
gender
M 42 29 23 16 7
F 17 13 8b 5 4
syndromic
no 49 36 26b 18 9
yes 10 6 5 3 2
RET mutation
no 45 31 22b 17 6
yes 14 11 9 4 5
5′ haplotype
risk homo 46 31 23b 17 7
risk het 1 1 0 0 0
no risk 6 (3 + 3) 5 4 3 1
rare 3 3 2 1 1
unknown 3 2 2 0 2
tot patients 59 42 31b 21 11
tot aberrations 77 (+ 6 control regions) 37 25 12
a excluded the four control regions and the region of trisomy for the two HSCR patients with associated Down syndrome. 7q21.11 del found in HSCR005 is
included among those “not reported” (last column) although present on DGV database, but at a very low frequency
b the sum of patients with “true” variants reported and not reported on DGV is different from the overall number of patients with “true” variants as one patient
displayed two true aberrations, one on DGV and another one not on DGV
Lantieri et al. Orphanet Journal of Rare Diseases          (2019) 14:270 Page 12 of 16
novo occurrence. Similar observations have already been
made in Type 2 Diabetes (T2D) (OMIM# 125853) and
long QT syndrome (OMIM# 192500) [46, 47] and it has
also been demonstrated that inherited CNVs might be
pathogenic [48]. Interestingly, an increase in CNV burden
in the mothers of children affected by mental retardation
(MR) have been recently reported in the Chinese popula-
tion, suggesting that females might be more tolerant than
males to deleterious variations and that MR manifestation
for females might require a higher burden of deleterious
variants [49]. Consistent with our observation of an excess
of inheritance from unaffected mothers, a parental muta-
tion transmission asymmetry has already been reported at
the RET locus [50]. Apparently, this bias in the transmis-
sion of RET single base mutations was not due to different
expression of the disease depending on the gender of the
transmitting parent, but rather to differential reproductive
rate between male and female carriers, with mothers carry-
ing a severe mutation that would be more likely than fa-
thers to reproduce and transmit [50]. Considering that
HSCR penetrance is less reduced in male than females, with
recurrent risk for male sibs higher when the HSCR patient
is female [1, 5], the differential paternal and maternal fitness
and the supposed greater mutation burden toleration in fe-
males seem to be the two faces of the same coin. Therefore,
asymptomatic females carrying these HSCR structural vari-
ants would be more likely to transmit the causative CNV
alleles, as already demonstrated in other diseases, especially
in the presence of additional alterations.
Conclusions
Three fundamental genes already involved in HSCR
pathogenesis, namely SEMA3A/3D, NRG1 and
PHOX2B, have been shown in our study to play a
role also through the presence of CNVs, thus suggest-
ing their haploinsufficiency is responsible of damaging
effects. Indeed, to our knowledge the presence of
structural variants in HSCR patients has never or
rarely been reported for NRG1, SEMA3A/3D, and
PHOX2B. Conversely RET involvement in HSCR does
not seem to rely on the presence of CNVs but, inter-
estingly, several gains and losses did co-occur with
another RET defect in our sample, thus sustaining the
hypothesis that more than one predisposing event is
necessary for HSCR to develop. Our results, not sur-
prisingly for a complex genetic disease like HSCR,
support a role of candidate genes in transcription and
expression regulation and in ENS development, con-
firming the known genetic heterogeneity and showing
the possible involvement of new loci. Finally, all the
CNVs shown to be inherited in our samples were of
maternal origin, including the four novel CNVs de-
tected on 9q31 affecting patients who were also carry-
ing variants of the RET proto-oncogene.
Methods
HSCR patients and microarray design
A total of 55 Italian sporadic HSCR patients were retro-
spectively included in the study, as described under the
“Results” section.
We performed high-resolution oligonucleotide array-
CGH analyses on 20 candidate genes/loci known to be
involved in HSCR, using a customized 8x15K array (Agi-
lent Technologies, Santa Clara, CA, USA), in accordance
with manufacturers’ instructions, whose details are re-
ported in Table 1. Additional probes were also distrib-
uted along the whole genome, including those useful for
sample replication and normalization. Genomic posi-
tions are based on the Human Genome GRCh37 (hg19)
assembly (http://genome-euro.ucsc.edu).
Data analysis
To assess genomic imbalances, we applied the Aberra-
tion Detection Methods ADM-2 with a threshold of 6,
as recommended by Agilent. We also applied the
centralization and the GC correction algorithms and
considered as aberrant only those regions with a mini-
mum of 2 consecutive probes and exceeding a Mean
Absolute Log2 Ratio of 0.30 (referred as MALR> 0.30).
In addition, sample profiles were evaluated at the whole
genome level by visual inspection. Such a manual search
was performed paying attention to log2 ratios values
above 0.5 and below − 1.0 and taking into consideration
not only the overall profile of the single individual sam-
ple (and its quality) but also the profiles of the entire co-
hort. The above parameters were kept, with the
exception of the MALR> 0.30 filter, and observations
were confirmed by a second operator. Based on such in-
spection, we classified the CNVs detected as “likely”,
“possible”, or “unlikely”. Loci with nearby gain or loss in-
tervals and an intervening region of more than 2 probes
were considered as separate CNVs, as well as those dif-
fering for 2 probes with opposite log2 ratios (log2ratio <
− 0.3 for gain and > 0.3 for deletions). The quality of the
experiments was evaluated on the basis of the QC met-
rics generated by the Genomic Workbench 5.0.14 soft-
ware (Agilent Technologies), such as the DLRSpread
(derivative log ratio spread), a measure of the log ratio
noise for each sample. DLRSs and the other sample met-
rics are detailed elsewhere [30].
Ten samples with bad profiles (DRLS ≥0.3) together
with other 16 arbitrarily selected samples, were repli-
cated at least once on another array, for a total of 26
samples with at least one replicate. The successive vari-
ants search was performed in the replicates of overall
better quality.
Aberrations were compared with CNVs observed in
the normal population, as reported in the Database of
Genomic Variants (DGV, http://dgv.tcag.ca/dgv/app/
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home), and with the CNVs reported in the DECIPHER
database of phenotypes, v8.7 release (https://decipher.
sanger.ac.uk/). Data comparing is challenging as exact
boundaries of the aberrations are not known, but only
assumed to be between the last “normal” probe (outer)
and the first “aberrant” probe (inner), depending on the
mean coverage. However, we considered aberrations as
consistent with those already reported if they showed an
overlap ≥80%, did not differ for more than two probes
with compatible log2 ratios (that is ≥ |0.3|), and were of
the same kind (gain or loss).
To get further insight into the aberrations thus identi-
fied, we also compared their frequencies in our sample
with frequencies of corresponding CNVs publically avail-
able at a resolution similar to that of our design, consid-
ering comparable those CNVs with identical boundaries
(Additional file 2). To this end we used the control data
from the European population in the GnomAD website
(https://gnomad.broadinstitute.org/) and from the DDD
database, browsed through the UCSC genome browser
(https://genome-euro.ucsc.edu/index.html), and assessed
statistical differences through the Fisher’s test or the
Chisquare test with Yate’s correction for continuity
when more feasible.
Validation
Results obtained with the custom aCGH, together with
the concordance degree among the replicates on the same
design array, showed that the replication rate was not very
high, and that the visual inspection outperformed the
mere software call [30]. However, a high false positive rate
is not surprising as a few studies have shown a not infre-
quent presence of false positive and false negative results
from aCGH [51–54]. As a matter of the fact, Conrad et al.
(2010), using quantitative PCR (qPCR) for initial valid-
ation of aCGH experiments on 450 HapMap samples, sug-
gested a preliminary false-discovery rate of ~ 20%, then
assessed to 15% when comparing the results with another
CNV-typing array [55].
For this reason, the most promising regions, based on
rare presence/absence on DGV and visual inspection,
were selected to undergo validation with different ap-
proaches. Parents were also investigated, when available,
to verify whether the aberrations were inherited or de
novo. When the deleted region was sufficiently small,
the DNA was amplified with PCR and checked for
anomalous bands by electrophoresis. For the majority of
the aberrations, validation was carried out applying
quantitative PCR. Primer pairs were designed with
Primer-blast (http://www.ncbi.nlm.nih.gov/tools/primer-
blast/) according to stringent parameters to ensure suc-
cessful assay. qPCR analysis was performed with the
LightCycler 480 Instrument and relative software using
the SYBR Green I Master following manufacturer’s
recommendations (Roche, Manheim, Germany). In case
of inconclusive results, we spotted the sample on a CGH
8x60K array (Agilent).
The probability that 7 out of 7 inherited CNVs were
transmitted by mothers was checked by the binomial
test.
Finally, we defined variant as “true” when either re-
ported on DGV, confirmed on a second array replicate,
or validated with a different approach as described
above.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13023-019-1205-3.
Additional file 1. “Variants detected by software and visual inspection,
according to selection criteria”. Whole raw data obtained by applying the
a-CGH approach.
Additional file 2. “Frequencies of CNVs detected in our sample
compared to those for controls from gnomAd and DDD”. Comparison of
all the aberrations detected by aCGH in our study and the frequencies
reported for controls in two databases.
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